http://vir.sgmjournals.org/content/early/2012/01/12/vir.0.039909-0.abstractDiscovery of drugs that possess activity against feline leukemia virus
+ Author Affiliations
- ↵1 E-mail: mansky@umn.edu
- Received 22 November 2011.
- Accepted 12 January 2012.
Abstract Feline leukemia virus (FeLV) is a gammaretrovirus that is a significant cause of neoplastic-related disorders affecting cats worldwide. Treatment options for FeLV are limited, associated with serious side effects, and can be cost-prohibitive.
The development of drugs used to treat a related retrovirus, HIV-1, has been rapid leading to the approval of 5 drug classes. Although structural differences affect the susceptibility of gammaretroviruses to anti-HIV drugs, the similarities in mechanism of replication suggest that some anti-HIV-1 drugs may also inhibit FeLV.
his study demonstrates the anti-FeLV activity of four FDA approved drugs at non-toxic concentrations. Of these, tenofovir and raltegravir, are anti-HIV-1 drugs while, decitabine and gemcitabine, are approved to treat myelodysplastic syndromes and pancreatic cancer, but also have anti-HIV-1 activity in cell culture.
Our results indicate that these drugs may be useful for FeLV treatment and should be investigated for mechanism of action and suitability for veterinary use.
---------------------------------------------------
In addition, recent studies have shown that tenofovir and raltegravir exhibit antiviral
70 activity against, a related gammaretrovirus xenotropic murine leukemia related virus (XMRV)
71 (Paprotka et al., 2010; Singh et al., 2010; Smith et al., 2010). ...
